News

Paradigm4 Launches Precision Cell Atlas™

Paradigm4 has launched the Precision Cell AtlasTM as an integral component of its REVEALTM: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse, and regulatory filings.

REVEAL: SingleCell, together with the Precision Cell Atlas capability, includes industry standard statistical tools to assess the sample-to-sample variation in gene vectors while retaining the provenance from the original project metadata for each sample. Metadata is tracked in the immutable log files recorded with REVEAL: SingleCell.

With its initial launch in 2020, REVEAL: SingleCell was developed to offer biopharmaceutical computational biologists the ability to break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets. The app enables users to navigate multimodal disease biology, scale to handle more samples from patients with more cells, more features, and diverse data types. Users can readily assess key biological hypotheses for target evaluation, disease progression, and precision medicine applications.

Paradigm4’s REVEAL suite of use case-specific applications were built to transform scalable translational understanding from whole body to organelle. Other apps developed by Paradigm4 include REVEALTM: Proteomics and REVEALTM: Biobank. The apps are powered by Paradigm4’s unique technology stack, designed for scalable and interactive exploration, analytics, and machine learning on heterogeneous and highly dimensional scientific data sets.

Zachary Pitluk, Ph.D., VP of Life Sciences and Healthcare at Paradigm4, commented: “Since its launch, REVEAL: SingleCell has been embraced by the single cell analysis community, with as many as 80 million cells in play in some installations. Current customer installations are supporting thousands of queries per day with the present implementation. Importantly, the addition of the Precision Cell Atlas functionality should increase the supportable queries and drive projects forward at a much faster rate than is currently available.”

For more information about Paradigm4, visit https://paradigm4.com/.

whitepages icon x

World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

Bio-IT World || Lessons From the Recent HCA 2022 General Meeting: Applying Single-Cell Data to Clinical Decision Making

The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights

whitepages icon x

Drug Discovery World | Are scalable data science platforms the way forward?

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.